2009
DOI: 10.1002/msj.20116
|View full text |Cite
|
Sign up to set email alerts
|

Balancing Risk and Benefit with Oral Hypoglycemic Drugs

Abstract: Clinicians are faced with an expansive array of treatment choices when caring for patients with type 2 diabetes. Because patient compliance may be affected when media sensationalism about controversial findings is misunderstood, we sought to clarify the recent controversy surrounding the cardiovascular and bone-health risks of thiazolidinediones, the risk of lactic acidosis with metformin, and the risk of hypoglycemia with oral therapies. The side effect profile of thiazolidinediones includes fluid retention, … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
23
0

Year Published

2009
2009
2017
2017

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 33 publications
(23 citation statements)
references
References 108 publications
0
23
0
Order By: Relevance
“…Metformin is contraindicated in patients with these conditions and/or current exposure to intravascular radiographic contrast. The incidence of lactic acidosis in patients without these risk factors is very low; however, these risks are over-represented in obese subjects [12].…”
Section: Metforminmentioning
confidence: 99%
“…Metformin is contraindicated in patients with these conditions and/or current exposure to intravascular radiographic contrast. The incidence of lactic acidosis in patients without these risk factors is very low; however, these risks are over-represented in obese subjects [12].…”
Section: Metforminmentioning
confidence: 99%
“…angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB)) are used for the treatments of chronic kidney failure, diabetic nephropathy, and hypertension [29, 30], which could also induce hyperkalemia (a condition characterized by high blood levels of potassium). Endothelin receptor antagonists (ERA) [31] and oral hypoglycemic drugs [32] are used to treat hypertension and kidney disease in diabetic patients, but these drugs also have adverse effects, including fluid retention and edema [33]. With the ability to deliver a wide range of therapeutics specifically to disease locations and in a sustained manner, nanomedicines are emerging as new treatments with the potential to minimize the adverse effects of current EnD therapies.…”
Section: Endothelial Function and Dysfunctionmentioning
confidence: 99%
“…However, insulin therapy has a number of risks associated with it including, hypoglycaemia, weight gain, and increased risk of colorectal cancer [47]. These risk factors together with the route of administration (usually subcutaneous injection); contribute too many patients being reluctant to maintain intensive insulin therapy [48].…”
Section: Approaches and Goals For The Treatment Of Type 2 Diabetesmentioning
confidence: 99%